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The tendency of amyloid b (Ab42) peptide to misfold and aggregate into insoluble amyloid fibrils in Alzheimer’s
disease (AD) has been well documented. Accumulation of Ab42 fibrils has been correlated with abnormal apoptosis and
unscheduled cell division which can also trigger the death of neuronal cells, while oligomers can also exhibit similar
10 activities. While investigations using chemically-synthesized Ab42 peptide have become common practice, there appear
to be differences in outcomes from different preparations. In order to resolve this inconsistency, we report 2 separate
methods of preparing chemically-synthesized Ab42 and we examined their effects in yeast. Hexafluoroisopropanol
pretreatment caused toxicity while, ammonium hydroxide treated Ab42 induced cell proliferation in both C. glabrata
and S. cerevisiae. The hexafluoroisopropanol prepared Ab42 had greater tendency to form amyloid on yeast cells as
15 determined by thioflavin T staining followed by flow cytometry and microscopy. Both quiescent and non-quiescent
cells were analyzed by these methods of peptide preparation. Non-quiescent cells were susceptible to the toxicity of
Ab42compared with quiescent cells (p < 0.005). These data explain the discrepancy in the previous publications about
the effects of chemically-synthesized Ab42 on yeast cells. The effect of Ab42 on yeast cells was independent of the size
of the peptide aggregates. However, the Ab42 pretreatment determined whether the molecular conformation of
20 peptide resulted in proliferation or toxicity in yeast based assays.
Introduction
Soluble oligomers of amyloid b (Ab42) peptide have been
found to be highly neurotoxic and important in the etiology of
AD in comparison to fibril forms.1 However, it is still unknown
25 which form of the aggregates are more dangerous; oligomers and
protofibrils or fibrils and filaments.2-4 Despite these uncertainties
aggregation studies in search for chemo-preventatives that block
Ab42 oligomer and fibril formation using synthetic forms of
Ab42 have become common practice.
5-8
30 The preparation of Ab42 peptide can affect its amyloidogenic-
ity4 yet pretreatments are required in order to produce mono-
mers.9 Lioudyno et al.10 reported that pretreatment with
1,1,1,3,3,3-hexafluoroisopropanol (HFIP) enhanced the amyloi-
dogenicity of the Ab42 peptide as well as its interaction with bio-
35 logical membranes.
Complex mechanisms contribute to development of AD. Syn-
aptic loss due to plaque formation11 and neuronal death due to
oligomeric forms of Ab42 are all hallmarks of the disease.
12 It has
been reported that different conformations of Ab42 induce neu-
40 rotoxicity by distinct mechanisms in human cortical neu-
rons.13,14 The longer variants have higher propensity to
aggregation than the shorter form.13 The mechanism of Ab42
toxicity is still unknown, although it is suggested that amyloido-
genic protein aggregates on neuronal cells cause permeabilisation
45of lipid membranes,15-17 and increase oxidative stress,18,19 mito-
chondrial dysfunction,20-22 and endoplasmic reticulum stress23,24
which ultimately leads to apoptosis.
Yeast exhibit some responses to Ab42 peptide that indicate
they are good models for studying the effects of on neuronal
50cells.25 However, some limitations are expected since yeast
lack receptors that have been proposed for Ab42 binding. Puta-
tive receptors include the insulin receptor,26 the alpha7 nicotinic
receptor,27 the metabotrophic glutamate receptor,28 and cellular
prion protein.29 Chacinska and colleagues30 showed an induction
55of proliferation in the presence of synthetic Ab42 in exponentially
growing Saccharomyces cerevisiae, while Bharadwaj et al.31
showed toxicity of synthetic Ab42 with a different preparation
method on Candida glabrata cells. In this study we report on the
preparation of Ab42 peptide with 2 different methods and treat-
60ments of identical yeast cell cultures. The two pretreatments
resulted in totally opposite outcomes.
Results
Pretreatment determines the activity of Ab42 peptide
HFIP pretreatment of Ab42 was previously shown to cause
65toxicity to C. glabrata cells.31 This study confirms significant tox-
icity of HFIP pretreated Ab42 to C. glabrata (Fig. 1A) and to
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S. cerevisiae (Fig. 1B). There was even more cell killing after 48 h
of incubation. Conversely, NH4OH pretreatment resulted in a
significant increase in the number of yeast cells. C. glabrata
70 (Fig. 1A) more than doubled in number (P< 0.001), and S. cere-
visiae (Fig. 1B) numbers significantly increased over the time
(P < 0.005).
Susceptibility of quiescent and non-quiescent cells to toxic
Ab42
75 Stationary phase fractions of C. glabrata were tested for their
susceptibility to 2 mM Ab42 generated by HFIP pretreatment
method. Results indicated that quiescent daughter cells (Fig. 2A)
are more resistant to the toxic effect of Ab42 than older non-qui-
escent mother cells (Fig. 2B). The older cells lost their viability
80 within 24 h in the presence of amyloid peptide whereas younger
cells were affected by the toxicity after 48 h of incubation (see
Fig. 2).
Amyloid staining on the yeast cell surface and aggregation
propensity
85 In order to examine the presence of amyloidogenic proteins
on the surface of yeast cells ThT treated cells were visualised for
fluorescence. S. cerevisiae exhibited presence of a high level of
ThT stained proteins on their surface (Fig. 3). Yeast treated with
HFIP prepared Ab42 on the other hand
90have more aggregation propensity, caus-
ing the cells to adhere and attach to each
other (see Figs. 3G, I). Cell aggregation
appears absent in those cells treated with
NH4OH prepared Ab42 (Figs. 3D, F).
95This result indicates that peptide pro-
duced by each method of preparation
interacts differently with the yeast cell
walls.
Flow cytometry for analysis
100of fluorescence intensity associated
with peptide
The fluorescence intensity associated
with ThT level on the surface of the yeast
cells treated with HFIP- and NH4OH-
105prepared amyloid peptide was measured by flow cytometry. Data
showed an increase in the fluorescence intensity (FI) in the pres-
ence of HFIP pretreated peptide (Fig. 4C) compared with the
NH4OH method (Fig. 4D), and untreated controls (Fig. 4A):
fluorescence intensity was measured to be 8.4%, 5.4% and 3.7%
110respectively (see Figs. 4C, D). It seems the peptide conformation
generated from the HFIP method has a greater propensity to
induce aggregation and may cause amyloid deposition on the sur-
face of yeast cells.
TEM analysis of peptide conformers generated by
115pretreatment
The Ab42 prepared for viability counts was analyzed by TEM.
The NH4OH method resulted in more uniform aggregate free
peptide solution (Fig. 5A) compared with HFIP (Fig. 5C). The
latter showed the presence of protofibrils structures at 0 h. After
12024 h incubation at 37C short fibrils were observed in NH4OH
prepared peptide (Fig. 5B) while, the HFIP method (Fig. 5C)
resulted in long and twisted fibrils (Fig. 5E).
Effect of fibrils on the yeast cells
The toxicity of fibrils, formed after prolonged incubation, was
125examined. Fibrils generated from HFIP and NH4OH pretreat-
ment were both toxic to yeast cells (Fig. 6). However, HFIP pre-
pared Ab42 fibrils exhibited greater
toxicity compared to those fibrils pre-
pared with NH4OH.
130Discussion
The current study indicates that differ-
ent preparations of Ab42 peptide can lead
to different biological activity toward
yeast. The recently introduced NH4OH
135pretreatment of synthetic Ab42 reportedly
results in formation of higher levels of
monomeric peptide32 and has not previ-
ously been tested on yeast. Soluble
Figure 1. Effect of HFIP and NH4OH pretreated synthetic Ab42 on the yeast cells. 2 mM peptide was
added to exponential phase C. glabrata (A) and S. cerevisiae (B) cells, suspended in water. Samples
were incubated at 30C for 48 h. Viability was determined as percentage of untreated cells (control).
(* P < 0.05, ** P < 0.01, *** P< 0.005, and **** P < 0.001). Data are shown as Mean § SEM.
Figure 2. Effect of Ab42 on the quiescent and non-quiescent fractions of C. glabrata. The quiescent
daughter cells (A) were more resistant to Ab42 prepared with HFIP method than non-quiescent
mother cells (B) in the first 24 h of incubation. After 48 h of incubation both cell fractions were sus-
ceptible to the toxicity effect of Ab42 (*** P < 0.005).
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monomers of the Ab42 prepared by NH4OH caused cell prolifer-
140 ation and an increase in the number of colonies in both S. cerevi-
siae and C. glabrata, regardless of the type of solvent (H2O or
dilute NaOH). With prolonged incubation more fibrils were
formed and these were toxic to S. cerevisiae cells.
In contrast, the Ab42 peptide prepared by the HFIP method
145 contained high levels of aggregates and caused cell death within
the first 24 h as well as after this time. Older cells were shown to
be more susceptible to the effects of Ab42. The Ab42 peptide con-
formation appears to be the major determinant of its effect on
yeast cells. Previous studies showed that Ab42 prepared using
150 HFIP tends to be more potent in the electrophysiological tests
and has a greater tendency to modulate biological membrane
properties.4,9,10 To further investigate the different outcomes
caused by HFIP, it would be worth examining if HFIP affects
the toxicity of additional fibril forming peptides.
155 The attachment of the Ab42 peptide to the yeast cell surface
has been demonstrated by Bharadwaj (2011) who demonstrated
direct binding of fluorescein-labeled Ab42 to the cell surface by
fluorescence microscopy.33 This finding was further confirmed
by electron microscopy and western blotting of sub-cellular
160fractions.33 In this study we showed that the Ab42 peptide caused
increased ThT staining of the yeast cell surface. Without Ab42
peptide treatment, there was some ThT staining which may be
attributed to proteins such as Flo1p, Als1p, Als5p, Muc1p and
Bgl2p.34-37 While there is clear evidence for peptides from
165Flo1p, Als1p, Als5p, and Muc1p to be amyloid forming, the evi-
dence for these proteins forming amyloid on the yeast surface is
currently incomplete and limited to the birefringence and ThT
staining that they cause.36 While it is tempting to speculate that
Ab42 may be forming amyloid on the yeast cell surface, proof of
170amyloid formation requires analysis of the resistance to an ionic
detergent. This evidence is still lacking for other yeast cell surface
proteins.
HFIP-treated Ab42 resulted in peptide with long strand fibril
morphology compared with the NH4OH method. It is known
175that HFIP pretreatment method does not efficiently generate
aggregate free solutions. This HFIP pretreatment results in pep-
tide that has a high propensity to adhere to the yeast cell wall. In
this form the peptide in any size, monomeric, oligomeric and
even fibrils are toxic to yeast cells. On the other hand, Ab42 that
180is freshly pretreated with NH4OH caused cell proliferation due
Figure 3. Staining of amyloid proteins present on S. cerevisiae cell walls by thioflavin T. First row (A–C) shows untreated S. cerevisiae cells in presence of
ThT in comparison with cells treated with 5 mM NH4OH (D–F) and HFIP (G–I) prepared Ab42 for 24 h in H2O. ThT staining comparison of untreated (con-
trol), NH4OH and HFIP pretreated cells are shown in panels A, D and G respectively. The HFIP pretreatment of Ab42 results in higher fluorescence intensity
and adhesion of peptide to the S. cerevisiae yeast cell wall protein. Scale bar D 50 mm.
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to monomeric and oligomeric forms while prolonged incubation
led to a fibrillar conformation which was toxic to S. cerevisiae
cells.
The data presented here show that different methods for the
185 preparation of Ab42 can lead to different biological activities in
in vitro and in yeast biological assays. This work should serve as a
caution in working with and interpreting the outcomes of biolog-
ical assays.
Materials and Methods
190 Yeast strains and growth conditions
C. glabrata (ATCC90030) and S. cerevisiae BY4743 (a/a
his3D/his3D leu2D/leu2D C/lys2D met15D/C ura3D/ura3D)
were utilised for experiments and were grown in YEPD (1%
yeast extract, 2% peptone, and 2% D-glucose) with aeration at
195 30C. For fractionation of quiescent and non-quiescent cells,
growth in the YEPD media continued for 7 d with shaking
(200 rpm). Cells were subsequently pelleted and washed for
further analysis. For exponential phase of growth, yeast cells
were grown overnight and were har-
200vested by centrifugation the next day
and resuspended in 20 ml fresh media.
Then one ml was inoculated into
80 ml of fresh media and incubated at
30C with shaking (200 rpm) for
205another 2-3 h to reach an OD600 of
1.0.
Fractionation of stationary phase
C. glabrata and S. cerevisiae
Percoll density gradients (GE
210Healthcare, United Kingdom) were
prepared according to the man-
ufacturer’s preformed gradient proto-
col and method described by Allen
et al.40 with some modification.
215Briefly, Percoll was diluted 9:1 (v/v)
with 1.5 M NaCl. To form a gradient
10 ml of the Percoll solution was
added to 15 ml Corex tubes and cen-
trifuged for 15 min at 20C in a
220Beckman Coulter centrifuge (SW41Ti
rotor). Stationary phase yeast cells
which were grown for 7 d at 30C
with shaking were then pelleted and
resuspended in 1 ml Tris buffer
225(50 mM, pH 7.5). Around 2 ml of
cell suspension was overlaid onto pre-
formed gradient, and centrifuged at
400 g for 60 min in a Beckman Coul-
ter centrifuge. Fractions of quiescent
230(lower fraction) and non-quiescent
cells were collected and washed twice
in 40 ml Tris buffer to remove any
Percoll residue, pelleted and then resuspended in ddH2O.
Preparation of Ab42 peptide
235Synthetic human Ab42 peptide was purchased from Keck lab-
oratories (Yale University, New Haven, CT). The peptide was
synthesized and purified using tBOC chemistry with DCC and
HOBT coupling reagents in the form of lyophilized powder. All
solvents used for the preparation of Ab42 solutions were filtered
240and centrifuged to minimise the presence of debris that could
induce aggregation of the peptide.
Preparation of Ab42 using NH4OH
Peptide solutions were prepared according to the protocol of
Ryan et al.32 Briefly, 20 mg peptide was dissolved in 40 ml of
24510% NH4OH to final concentration of 0.5 mg/ml solution (w/
v). The solution was then left at room temperature for 10 min
and then sonicated for 5 min. For yeast treatments, the peptide
was prepared immediately prior to use. Each 0.5 mg aliquot of
Ab pellet was dissolved in 60 ml of ddH2O and then vortexed to
250promote the dissolving of the peptide. The solution was then
sonicated for 5 min and centrifuged at 14,000 g for 5 min to
Figure 4. Flow cytometry analysis of S. cerevisiae treated with HFIP and NH4OH prepared Ab42. The
fluorescence intensity (FI) of ThT in the experimental samples was determined as a percentage of
unstained cells. Yeast cells were grow to exponential phase, washed and resuspended in H2O. The
cells were then treated with HFIP and NH4OH pretreated Ab42 and incubated overnight along with
control (untreated samples) at 30C with shaking. The next day, cells were treated with 20 mM ThT
and were analyzed by flow cytometry. Pacific blue filter was chosen to measure fluorescence.
Unstained control cells (A), ThT stained control cells (B) and those treated with 5 mM of HFIP (C), and
NH4OH pretreated Ab42 have been shown.
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pellet any undissolved peptide. The
supernatant was carefully recovered for
use in subsequent assays. Peptide con-
255 centration was determined from the
A214nm measurement of the solution in a
quartz cuvette (BioMateTM Spec,
Thermo Scientific, UK).
Preparation of Ab42 using HFIP
260 Ab42 was dissolved in 1,1,1,3,3,3-
hexafluoroisopropanol (HFIP) accord-
ing to the method described by Cre-
scenzi and colleagues.39 Briefly the
peptide film was dissolved in HFIP to a
265 concentration of 1 mg/ml, sonicated for
5 min on ice and dried overnight to
form a clear film. The film was subse-
quently dissolved in 60 ml of ddH2O,
sonicated for 5 min and centrifuged to
270 remove insoluble aggregates. Peptide
concentrations were determined
described above.
Effect of prolonged incubation
of Ab42 on the survival of yeast
275 The Ab42 samples from each pre-
treatment method were incubated at
35C for 6 d. Exponentially growing
S. cerevisiae were washed and suspended
in H2O and then were treated with
280 5 mM of HFIP and NH4OH pretreated peptide and incubated
overnight. Treatment and viability were determined as follows.
Exponentially growing yeast cells were washed twice and
resuspended in ddH2O. After estimation of cell numbers by a
haemocytometer, cells were transferred into 96-well culture plates
285 at a concentration of 103 cells/ml, treated with 2-5 mM of Ab42
peptide in a final volume of 200 ml per microtiter well and incu-
bated overnight at 30C with shaking. The next day 100 ml ali-
quots of cell suspension were plated onto YEPD plates and
incubated for 2 days at 30C. Colonies were counted for each
290 treatment and the viability was estimated as percentage of
untreated cells. All treatments were performed in triplicate.
Flow cytometry analyses after Thioflavin T staining
of treated cells
Exponentially growing S. cerevisiae were washed and incu-
295 bated in H2O in the presence and absence of pretreated HFIP
and NH4OH peptide. After 16 h of incubation, Thioflavin T
(ThT) was added to each sample to a final concentration of
20 mM and incubated for 10 min.40 Around 10,000 cells per
sample were analyzed by flow cytometry (FACS, Canto II-
300 BDTM) using a pacific blue filter with 351 nm excitation and col-
lecting fluorescent emission at 450/65. Data were recorded and
saved as FCS3 files. All data were analyzed by WEASEL (WEHI,
Melbourne, Australia) software. ThT fluorescence intensity of
multiple experimental samples was calculated as percentage of
305unstained yeast cells.
Confocal microscopy after Thioflavin T staining
of treated cells
Confocal fluorescence and differential interference contrast
(DIC) microscopy was performed using a Nikon Eclipse Ti
310
315
320
325
Figure 5. TEM analysis of peptide pretreated by NH4OH and HFIP at 37C. The NH4OH method of olig-
omer formation (A) results in a higher amount of monomeric peptide compared with HFIP method in
which still contain long fibrils (B). After 24 h of incubation the NH4OH method of pretreatment (C)
induced a lower tendency form fibrils and those generated were shorter fibrils. The HFIP method (D)
on the other hand resulted in a higher level of twisted and longer fibrils. The HFIP twisted fibril is
shown (E). Scale bar D 200 nm.
Figure 6. Effect of aged peptide on yeast cells. The NH4OH and HFIP pre-
treated Ab42 peptide was incubated for 6 d at 37C with no shaking.
Exponentially growing S. cerevisiae were washed and suspended in H2O
and then treated with 2 mM of these aged peptides and incubated over-
night. Viability was determined the next day by transferring 100 ml of
treated and untreated samples onto YEPD solid agar. (* P < 0.05 and
**** P < 0.001).
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confocal laser-scanning microscope. Treated and untreated yeast
330 cells with Ab42 peptide in H2O in a 96 well microtiter plate were
stained with ThT to a final concentration of 20 mM. ThT fluo-
rescence was observed using a DAPI filter following excitation of
the sample with light of 405 nm wavelength. Images were
acquired using a Nikon camera and NIS-Elements imaging
335 software.
Transmission electron microscopy
Freshly prepared aliquots of Ab42 peptide with both pretreat-
ment methods were used for imaging the starting peptide confor-
mation. The peptide samples were then incubated overnight at
340 35C for analysis of peptide conformation after 24 h. Samples
from 0 and 24 h were gently agitated before transferring a 4 ml
aliquot onto the grids. After 30 sec adsorption time, the excess
sample was drawn off using Whatman 541 filter paper. The
grids were stained subsequently with 2% w/v potassium phos-
345 photungstate (pH 7.2) for 10 sec. The grids were then air dried
before examination. The samples were examined using a
TecnaiTM 12 Transmission Electron Microscope (FEI,
Eindhoven, The Netherlands) at an operating voltage of 120 kV.
Images were recorded using a Megaview III CCD camera and
350AnalySIS camera control software (Olympus Australia).
Statistical analysis
Graphs were made using Microsoft Office Excel 2010 soft-
ware and data were analyzed using PRISM 6 (Graph Pad Soft-
ware, Inc.., La Jolla, CA, USA). All data are presented as mean C
355SEM. Significant differences between samples were determined
by comparing the mean score of samples by an unpaired
Student’s t-test. A P-value of <0.05 is deemed as significant.
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